Potential Benefits of In Silico Methods: A Promising Alternative in Natural Compound’s Drug Discovery and Repurposing for HBV Therapy

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(3), P. 419 - 419

Published: March 16, 2025

Hepatitis B virus (HBV) is an important global public health issue. The World Health Organization (WHO) 2024 Global Report estimated that the prevalence of people living with HBV infection 254 million, incidence 1.2 million new infections yearly. Previous studies have shown natural compounds antiviral inhibition potentials. In silico methods such as molecular docking, virtual screening, pharmacophore modeling, quantitative structure–activity relationship (QSAR), and dynamic simulations been successfully applied in identifying bioactive strong binding energies treatment targets. COVID-19 pandemic necessitated importance repurposing already approved drugs using methods. This study aimed at unveiling benefits techniques a potential alternative compounds’ drug discovery for therapy. Relevant articles from PubMed, Google Scholar, Web Science were retrieved analyzed. Furthermore, this comprehensively reviewed literature containing identified essential proteins. Notably, hesperidin, quercetin, kaempferol, myricetin, flavonoids hepatitis surface antigen (HBsAg). investigation reveals offer understanding mechanisms action, reveal previously overlooked viral targets (including PreS1 Domain HBsAg cccDNA (Covalently Closed Circular DNA) regulators, facilitate creation specific inhibitors. integration silico, vitro, vivo insights further highlight Moreover, combination compounds, approach, improves chances personalized precision medicine treatment. Therefore, we recommend strategies combine vivo, approaches to effective drugs.

Language: Английский

Revolutionizing HCV Therapy: microRNA Approaches in New Era of Treatment

IntechOpen eBooks, Journal Year: 2024, Volume and Issue: unknown

Published: July 11, 2024

Since the development and evolution of COVID-19 immunization, use mRNA-based technologies has led to revolutionary changes due potential RNA-based therapies, which are believed be useful in treating many infectious diseases. Information on treatment hepatitis C virus (HCV) following this rule highlights therapeutic microRNAs (miRNAs). The advent direct-acting antivirals (DAAs) changed paradigm HCV treatment. However, challenges remain, particularly areas viral resistance, genetic diversity, chronic Among these, miRNAs a sensible approach complementing improving existing models. implementation new non-coding RNAs should investigated. This chapter discusses public awareness RNA (ncRNA) strategies against HCV. From modification discovery pathways focusing their applications, efficacy, As scientific community looks toward antiviral drugs, demonstrates that introduction drugs into health systems holds promise for addressing providing solutions such as drug persistence, more. New therapy not only expand scope but also define landscape increase flexibility adaptability face challenges.

Language: Английский

Unraveling the Mechanisms of MicroRNA in Suppressing Hepatitis B Virus Progression: A Comprehensive Review for Designing Treatment Strategies

Hepatitis Monthly, Journal Year: 2024, Volume and Issue: 24(1)

Published: Sept. 17, 2024

: Liver cancer and cirrhosis caused by the Hepatitis B virus (HBV) remain significant global health challenges due to virus's high prevalence contagious nature. can be transmitted through various means, leading mild or severe liver disease. Although an effective prophylactic vaccine is available, it offers limited benefits for those already chronically infected. Current treatments often fail consistently eliminate cause adverse effects. In response these challenges, researchers have begun exploring microRNAs (miRNAs) as novel therapeutic targets. Studying miRNA-virus interactions presents a promising opportunity identify potential By manipulating host miRNAs, aim enhance antiviral defenses, restore cellular balance, prevent viral replication. The text concludes highlighting personalized medicine in treatment, guided individual miRNA profiles. Numerous studies been conducted understand how different miRNAs inhibit HBV replication, paving way development of innovative strategies.

Language: Английский